Women’s Tennis Association tests player genes for eligibility

The Women’s Tennis Association recently launched a new policy requiring all players to undergo a one-time genetic test. This initiative establishes biological sex for eligibility purposes and aims to maintain fairness across the professional circuit. The organization notes that this move ensures equal athletic opportunities for all participants in the female category.

Under the guidelines, athletes undergo a single lifetime test to detect the SRY gene located on the Y chromosome. This process typically involves a simple cheek swab, blood, or saliva sample. If a player tests positive for the gene, they must provide medical documentation confirming Complete Androgen Insensitivity Syndrome or other specific developmental sex disorders to remain eligible.

This policy includes strict enforcement measures. Players are required to sign a document acknowledging that refusal to participate in the testing process could lead to disciplinary action. The association views this as a necessary step to protect the integrity of its competitive structure.

Tennis legend Martina Navratilova expressed support for the update. She noted that the association is reinforcing the standard that women’s tennis is for women. The change puts the WTA in line with other major organizations like World Boxing and World Athletics, which have already implemented similar testing protocols.

Other global governing bodies are also moving toward biological verification. The International Olympic Committee has announced plans to adopt SRY gene testing for the 2028 games in Los Angeles. As more groups adopt these standards, the focus on biological markers for competition eligibility continues to grow across professional sports.